NCT02067910View on ClinicalTrials.gov

Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome

PHASE3CompletedINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

February 28, 2019

Study Completion Date

August 31, 2019

Conditions

Sjögren's Syndrome

Interventions

DRUG

Abatacept SC

Weekly subcutaneous administration of 125 mg Abatacept

Trial Locations (1)

9700RB

University Medical Center Groningen, Groningen

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University Medical Center Groningen

OTHER

NCT02067910 - Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome | Biotech Hunter | Biotech Hunter